91 related articles for article (PubMed ID: 24295784)
1. N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients.
Coelho BA; Belo AV; Andrade SP; Amorim WC; Uemura G; da Silva Filho AL
Biomed Pharmacother; 2014 Mar; 68(2):185-9. PubMed ID: 24295784
[TBL] [Abstract][Full Text] [Related]
2. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
[TBL] [Abstract][Full Text] [Related]
3. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.
Kaysen GA; Levin NW; Mitch WE; Chapman AL; Kubala L; Eiserich JP
Blood Purif; 2006; 24(5-6):508-16. PubMed ID: 17077623
[TBL] [Abstract][Full Text] [Related]
4. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
Konukoglu D; Turhan MS; Celik V; Turna H
Indian J Med Res; 2007 Jun; 125(6):747-51. PubMed ID: 17704550
[TBL] [Abstract][Full Text] [Related]
5. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
Iovino F; Ferraraccio F; Orditura M; Antoniol G; Morgillo F; Cascone T; Diadema MR; Aurilio G; Santabarbara G; Ruggiero R; Belli C; Irlandese E; Fasano M; Ciardiello F; Procaccini E; Lo Schiavo F; Catalano G; De Vita F
Cancer Invest; 2008; 26(3):250-5. PubMed ID: 18317965
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
7. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
8. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.
Balsari A; Maier JA; Colnaghi MI; Ménard S
Lab Invest; 1999 Jul; 79(7):897-902. PubMed ID: 10418830
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
Granato AM; Nanni O; Falcini F; Folli S; Mosconi G; De Paola F; Medri L; Amadori D; Volpi A
Breast Cancer Res; 2004; 6(1):R38-45. PubMed ID: 14680499
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.
Vicioso L; Gonzalez FJ; Alvarez M; Ribelles N; Molina M; Marquez A; Perez L; Matilla A; Alba E
Am J Clin Pathol; 2006 Jan; 125(1):111-8. PubMed ID: 16482999
[TBL] [Abstract][Full Text] [Related]
11. Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
Metwally FM; El-mezayen HA; Ahmed HH
Med Oncol; 2011 Dec; 28 Suppl 1():S15-21. PubMed ID: 20725807
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of N-acetilglucosaminidase and myeloperoxidase activity in patients with endometriosis-related infertility undergoing intracytoplasmic sperm injection.
Lamaita RM; Pontes A; Belo AV; Caetano JP; Andrade SP; Cândido EB; Carneiro MM; Silva-Filho AL
J Obstet Gynaecol Res; 2012 May; 38(5):810-6. PubMed ID: 22435532
[TBL] [Abstract][Full Text] [Related]
13. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
Adams J; Carder PJ; Downey S; Forbes MA; MacLennan K; Allgar V; Kaufman S; Hallam S; Bicknell R; Walker JJ; Cairnduff F; Selby PJ; Perren TJ; Lansdown M; Banks RE
Cancer Res; 2000 Jun; 60(11):2898-905. PubMed ID: 10850435
[TBL] [Abstract][Full Text] [Related]
15. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
[TBL] [Abstract][Full Text] [Related]
16. Strychnine inhibits inflammatory angiogenesis in mice via down regulation of VEGF, TNF-α and TGF-β.
Saraswati S; Agarwal SS
Microvasc Res; 2013 May; 87():7-13. PubMed ID: 23395890
[TBL] [Abstract][Full Text] [Related]
17. Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients.
El Agouza IM; Eissa SS; El Houseini MM; El-Nashar DE; Abd El Hameed OM
Angiogenesis; 2011 Sep; 14(3):321-30. PubMed ID: 21553281
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
[TBL] [Abstract][Full Text] [Related]
19. Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia.
Lages EL; Belo AV; Andrade SP; Rocha MÂ; de Freitas GF; Lamaita RM; Traiman P; Silva-Filho AL
Biomed Pharmacother; 2011 Oct; 65(7):496-9. PubMed ID: 22004597
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
